From pathogen identification to disease prevention and cure: understanding how Sanger sequencing and fragment analysis is powering infectious disease research today

Infectious diseases present a great challenge to global health and its economy. The 2020 SARS- CoV-2 pandemic highlighted the importance of rapid identification, characterization and surveillance of the virus to limit pathogen spread, and development of novel vaccine platforms and therapeutic agents. Across the spectrum from discovery of the infectious agent to cure, genetic analysis tools play an invaluable role in enabling researchers at each step of their research journey. Capillary Electrophoresis is one such tool that is vital to genomics through its gold-standard Sanger sequencing workflow and fragment analysis approach.

In this webinar, we will demonstrate how the flexibility of capillary electrophoresis enables pathogen identification and surveillance, characterization of antibiotic resistance conferred through genetic evolution, and drug discovery and vaccine development against a variety of infectious agents.

Key topics:

• Application of Sanger sequencing and fragment analysis in SARS-CoV-2 surveillance,
  antiviral drug development and mRNA vaccine QC
• Characterization of HIV genome mutations leading to drug resistance and durable cure
  through CRISPR gene editing
• Understanding the microbiome and its influence on infectious disease pathology
• Benefits of the latest generation CE-based genetic analyzer, SeqStudioTM Flex in infectious
  disease research and therapeutic development